The emerging role of oncolytic virus therapy against cancer

Luke Russell, Kah-Whye Peng

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.

Original languageEnglish (US)
Article number16
JournalChinese Clinical Oncology
Volume7
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Oncolytic Virotherapy
Adenoviridae
Latvia
Oncolytic Viruses
Viruses
Human Enterovirus B
Measles virus
Vesicular Stomatitis
Vaccinia virus
Human Herpesvirus 1
Simplexvirus
Retroviridae
China
Neoplasms
Pharmaceutical Preparations
Therapeutics

Keywords

  • Antitumor immunity
  • Cancer
  • Oncolytic
  • Virus

ASJC Scopus subject areas

  • Oncology

Cite this

The emerging role of oncolytic virus therapy against cancer. / Russell, Luke; Peng, Kah-Whye.

In: Chinese Clinical Oncology, Vol. 7, No. 2, 16, 01.04.2018.

Research output: Contribution to journalReview article

@article{4040ac2e19394c48a54b239c1b0f28c1,
title = "The emerging role of oncolytic virus therapy against cancer",
abstract = "This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.",
keywords = "Antitumor immunity, Cancer, Oncolytic, Virus",
author = "Luke Russell and Kah-Whye Peng",
year = "2018",
month = "4",
day = "1",
doi = "10.21037/cco.2018.04.04",
language = "English (US)",
volume = "7",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "2",

}

TY - JOUR

T1 - The emerging role of oncolytic virus therapy against cancer

AU - Russell, Luke

AU - Peng, Kah-Whye

PY - 2018/4/1

Y1 - 2018/4/1

N2 - This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.

AB - This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.

KW - Antitumor immunity

KW - Cancer

KW - Oncolytic

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=85047007611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047007611&partnerID=8YFLogxK

U2 - 10.21037/cco.2018.04.04

DO - 10.21037/cco.2018.04.04

M3 - Review article

C2 - 29764161

AN - SCOPUS:85047007611

VL - 7

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 2

M1 - 16

ER -